>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Afzelin

Afzelin (Synonyms: Kaempferin, Kaempferol 3-O-rhamnoside, Kaempferol 3-O-α-L-rhamnopyranoside)

Catalog No.GC35262

Afzelin(Kaempferol-3-O-rhamnoside)은 Houttuynia cordata Thunberg에서 발견되는 플라보놀 배당체이며 항균 및 해열제, 해독제 제조 및 염증 치료에 널리 사용됩니다.

Products are for research use only. Not for human use. We do not sell to patients.

Afzelin Chemical Structure

Cas No.: 482-39-3

Size 가격 재고 수량
1mg Please Inquire Please Inquire
5mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Afzelin (Kaempferol-3-O-rhamnoside) is is a flavonol glycoside found in Houttuynia cordata Thunberg and is widely used in the preparation of antibacterial and antipyretic agents, detoxicants and for the treatment of inflammation. Afzelin attenuates the mitochondrial damage, enhances mitochondrial biogenesis and decreases the level of mitophagy-related proteins, parkin and PTEN-induced putative kinase 1. Afzelin improves the survival rate and reduces the serum levels of alanine aminotransferase and pro-inflammatory cytokines in D-galactosamine (GalN)/LPS -treated mice[1].

[1]. Lee SB, et al. Afzelin ameliorates D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure by modulating mitochondrial quality control and dynamics. Br J Pharmacol. 2017 Jan;174(2):195-209.

리뷰

Review for Afzelin

Average Rating: 5 ★★★★★ (Based on Reviews and 3 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Afzelin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.